Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...
Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient patients seeing a 14-month gain and 38% lower death risk. New final overall ...
The addition of LuPSMA to enzalutamide reduced the risk of death by 45% vs enzalutamide alone. The median OS was 34 months (95% CI, 30-37) with the combination compared to 26 months (95% CI, 23-31) ...
Mevrometostat combined with enzalutamide improved median rPFS to 14.3 months versus 6.2 months with enzalutamide alone in mCRPC patients. The combination therapy showed a higher objective response ...
Talazoparib and enzalutamide combination significantly improved overall survival in mCRPC patients compared to enzalutamide and placebo. The TALAPRO-2 study showed a median overall survival of 45.8 ...
Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone. The addition of [177Lu]Lu-PSMA-617 (LuPSMA; Pluvicto) to enzalutamide (Xtandi) extended overall ...
Journal of Nuclear Medicine February 2025, jnumed.124.268340; DOI: https://doi.org/10.2967/jnumed.124.268340 ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback